View Financial HealthBetterLife Pharma 배당 및 자사주 매입배당 기준 점검 0/6BetterLife Pharma 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-1.5%자사주 매입 수익률총 주주 수익률-1.5%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Jul 08Betterlife Pharma Engages Nucro-Technics to Complete the Last Glp Toxicology Study of Betr-001 Required by the Fda for Ind and Phase 1BetterLife Pharma Inc. has entered into an agreement with Nucro-Technics Inc. to conduct the last IND-enabling GLP toxicology study with BETR-001 for its planned IND and Phase 1 program. BETR-001 is 2-bromo-lysergic acid diethylamide (2-Br-LSD), a non-hallucinogenic derivative of LSD. BETR-001 is a potent neuroplastogen and an agonist of the 5-HT1B, 5-HT1D, and 5-HT1F receptors, which are clinically validated targets of migraine therapies, as well as the 5-HT2A receptors. BETR-001 is being developed initially for migraine and cluster headache, two disabling headache disorders with substantial unmet medical needs. The BETR-001 IND filing is projected for the First Quarter 2027.공시 • Jun 23BetterLife Pharma Inc. announced that it has received CAD 2 million in fundingOn June 22, 2026, BetterLife Pharma Inc. has closed the transaction.공시 • Jun 16BetterLife Pharma Inc. announced that it expects to receive CAD 2 million in fundingBetterLife Pharma Inc. has announced a non-brokered private placement of 10% convertible debenture of the company to raise gross proceeds of CAD 2,000,000 on June 15, 2026. The debenture are 100% convertible into common units of the company at a conversion price value of CAD 0.06 per unit and carry interest rate of 10% and with each unit comprising of one common share and one share purchase warrant exercisable at CAD 0.10 for three years from issuance. All securities issued in connection with the Financing will be subject to a statutory hold period of four months and one day from the date of issuance in accordance with applicable Canadian securities laws. A director and insider of the company intends to participate in the financing by subscribing for CAD 2,000,000 of the Debenture. The bonds will mature one year from closing. The transaction is expected to close on June 25, 2026.공시 • Apr 18BetterLife Pharma Inc. announced that it has received CAD 0.4996 million in fundingOn April 17, 2026, BetterLife Pharma Inc. closed the transaction. Dr. Ahmad Doroudian, chief executive officer of the company, subscribed for a total of 1,250,000 units under the offering.공시 • Apr 09BetterLife Pharma Inc. announced that it expects to receive CAD 0.5 million in fundingBetterLife Pharma Inc announced non-brokered private placement offering to issue 7,142,857 unit at an issue price of CAD 0.07 for the proceeds of CAD 499,999.99 on April 8, 2026. Each unit consisting of one common share in the capital of the company and one full common share purchase warrant. Each warrant will entitle the holder to purchase one common share at an exercise price of CAD 0.10 for up to two years following the date of the closing of the private placement. The offering is expected to close on or about April 17, 2026, and is subject to execution of agreements by the placees and to certain conditions, including, but not limited to, the receipt of all necessary regulatory approvals, including the approval of the Canadian Securities Exchange. All securities issued in connection with the offering will be subject to a four-month-and-one-day statutory resale restriction pursuant to applicable Canadian securities laws.공시 • May 28Betterlife Pharma Inc. Provides Scientific Update on Neuroplastogenic Activity of Betr-001BetterLife Pharma Inc. recently presented a scientific update at Bloom Burton Conference on May 5, 2025 in Toronto, Canada. The emerging new paradigm in treating psychiatric and neurological disorders is the ability of a drug to enable the brain to rewire by growing new dendrites and spines, which enables new connections between neurons. Thisphenon is called neuroplasticity and the drug that is able to induce such an effect is called a neuroplastogen. BetterLife reported data at the Bloom Burton Conference showing that BETR-001 is a potent neuroplastogen. Only BETR-001 treatment was able to significantly induce formation of new spines (green stain) in cultured neurons. Based on its excellent neuroplasticity data, its neuroreceptor activation profile and preliminary data obtained in animal models, BETR-001 is projected to be effective in treating various psychiatric and neurological disorders including depression, anxiety, PTSD, traumatic brain injury, migraines and neuropathic pain. BETR-001 is non-hallucinogenic and not a controlled substance. BetterLife has been granted a composition of matter patent on BETR-001 by the USPTO. BetterLife has had its BETR-001 pre-IND meeting with the FDA and has completed most of the required IND-enabling studies. The BETR-001 IND filing and start of human trials are projected for first first half of 2026.공시 • May 19BetterLife Pharma Inc., Annual General Meeting, Jul 23, 2025BetterLife Pharma Inc., Annual General Meeting, Jul 23, 2025.공시 • May 15BetterLife Pharma Inc. Provides Scientific Update of Mechanism of Action of BETR-001 in Treatment of Psychiatric DisordersBetterLife Pharma Inc. recently presented a scientific update at Bloom Burton Conference on May 5, 2025 in Toronto, Canada. BetterLife reported that its proprietary compound, BETR-001, is showing very promising preclinical data of its breakthrough ability to provide therapeutic effect in depression/an anxiety animal models. Current methods of treating depression/an anxiety primarily focus on increasing the level of one of the three neurotransmitters: serotonin, norepinephrine and/or dopamine in the brain. Each neurotransmitter has different receptor targets, and each receptor performs different functions. Current treatments are usually reuptake inhibitors such as SSRIs (selective serotonin reuptake inhibitors) and by increasing the amount of a neurotransmitter, all its receptors are activated. What is needed are new treatments that activate the neuroreceptors themselves, and more importantly, only selective subsets of these receptors. The therapeutic effects of BETR-001 seen in preclinical models are primarily driven by its activation (agonism) of serotonin's 5HT2A receptor. Not only does BETR-001 activate the 5HT2A receptor, which plays a key role in depression/an anxiety, this activation is via a mechanism that allows for a highly efficacious therapeutic effect without hallucinogenic side effects. This stands in contrast to other potent 5HT2A activators, such as LSD, psilocybin and other psychedelics. BetterLife has reported on the details of BETR-001 activation of the 5HT2A receptor previously (Lewis et al., Cell Reports, 2023). Recently studies have shown that the activation of the 5 HT2A receptor above 70% leads to hallucination (Wallach et al., Nature Communications, 2023). BetterLife believes that BETR-001's novel mechanism of action provides a new paradigm for treatment of psychiatric disorders such as depression, anxiety and PTSD. It activates the 5HT2A receptor partially but stays below the hallucination threshold. In addition, unlike LSD, psilocybin, MDMA and other such agents BETR-001 is not an activator of the 5HT2B receptor. Activation of 5HT2B has been linked to cardiac safety. The neuroreceptor selectivity of BETR-001 in this regard is another of its key advantages over other competitor agents. An additional benefit of BETR-001 is that repeated dosing does not induce tolerance, unlike classic agents like LSD. This allows daily administration if needed. Furthermore, the lack of hallucinations with BETR-001 means it is a non-controlled substance and patient self-administration at home is possible. Finally, an overarching property of BETR-001 is a very potent neuroplastogen. BetterLife has been granted a composition of matter patent on BETR-001 by the USPTO. BetterLife has had its BETR-001 pre-IND meeting with the FDA and has completed most of the required IND-enabling studies. The BETR-001 IND filing and start of human trials are projected for H1 2026. BetterLife is considering the development of BETR-001 for treatment of various psychiatric and neurological disorders. BETR-001 for treatment the treatment of various psychiatric and neurological diseases.공시 • Mar 31BetterLife Pharma Inc. Appoints Steven Sangha to its Board of DirectorsBetterLife Pharma Inc. announced it has appointed Dr. Steven Sangha to its Board of Directors. Dr. Sangha has over 25 years of business experience, including investment banking, business development and asset management. His extensive background with public company governance, compliance and finance has led him to run a successful Private Fund Family Office. Dr. Sangha holds a Doctorate of Dental Surgery from the University of Western Ontario in London, Ontario, and a Bachelor of Pharmaceutical Science from the University of British Columbia in Vancouver, British Columbia.공시 • Nov 27BetterLife Pharma Inc. Obtains Cardiac Safety Data for BETR-001BetterLife Pharma Inc. announced it has completed one of its IND-enabling cardiac safety studies of BETR-001. These GLP in vitro studies demonstrated that BETR-001 has minimal impact on the human ether- a-go-go-related gene (hERG) channel, an important ion channel for cardiac functioning.공시 • Oct 23BetterLife Pharma Inc. Obtains Favourable Genotoxicity Data for Oral BETR-001BetterLife Pharma Inc. announced it has completed one of its IND-enabling genotoxicity studies of BETR-001. The studies demonstrated that oral BETR-001, even at very high doses, does not show any evidence of bone marrow toxicity or mutagenic (DNA mutation) and clastogenic (chromosome damage) activities. The GLP genotoxicity studies conducted on BETR-001 included in vitro bacterial reverse mutation assay, in vitro micronucleus test, and in vivo micronucleus test in male and female rats. These studies are a critical component of the safety assessment required by the U.S. Food and Drug Administration (FDA) and needed for entry into clinical trials.공시 • Aug 29BetterLife Pharma Inc. announced that it expects to receive CAD 1.1 million in fundingBetterLife Pharma Inc announced a non brokered private placement offering of 7,333,333 units issued at a price of CAD 0.15 per unit for gross proceeds CAD 1,099,999.95 on August 29, 2024. Each unit consisting of one common share in the capital of the Company and one full common share purchase warrant. Each Warrant will entitle the holder to purchase one Common Share at an exercise price of CAD 0.20 for up to two years following the date of the closing of the Private Placement. The close is subject to the receipt of all necessary regulatory and other approvals which will be announced as soon as it has been completed.공시 • Jul 03BetterLife Pharma Inc. announced that it has received CAD 0.175 million in fundingOn July 2, 2024, BetterLife Pharma Inc. closed the transaction.공시 • May 15BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001BetterLife Pharma Inc. announced it has completed its animal GLP cardiopulmonary safety study of BETR-001. The study demonstrated that oral BETR-001 at doses over 100-fold the projected starting dose in upcoming human trials did not show any significant cardiopulmonary pharmacological safety issues in animals. Cardiopulmonary safety (also known as telemetry) studies investigate the effect of a drug in animals using surgically implanted transmitters to assess blood pressure, electrocardiography (ECG), lung respiration, body temperature, and general activity level. The BETR-001 cardiopulmonary study found no BETR-001 related effects on ECG intervals, respiratory parameters, core body temperature, or activity levels.공시 • May 03BetterLife Pharma Inc. Advances BETR-001 IND-Enabling StudiesBetterLife Pharma Inc. announced that it has advanced in its IND-enabling studies for BETR-001, a non-hallucinogenic derivative of LSD (lysergic acid diethylamide). The IND-enabling metabolism and genotoxicity GLP studies have been initiated. BetterLife has had its BETR-001 pre-IND meeting with the FDA, and projects to file the BETR-001 IND by end of 2024.공시 • Apr 13BetterLife Pharma Inc., Annual General Meeting, Jun 25, 2024BetterLife Pharma Inc., Annual General Meeting, Jun 25, 2024.공시 • Mar 05BetterLife Pharma Inc. announced that it expects to receive CAD 0.1 million in fundingBetterLife Pharma Inc. announced a private placement to issue convertible debentures for the gross proceeds of CAD 100,000 on March 4, 2024. The transaction will include participation from individual investor such as Ahmad Doroudian for CAD 100,000.공시 • Mar 04BetterLife Pharma Inc. announced that it has received CAD 0.065 million in fundingBetterLife Pharma Inc. announced a private placement to issue 10% convertible debentures for the gross proceeds of CAD 65,000 on March 4, 2024. The Convertible Debentures are convertible at the option of the holder into units of the Company, consisting of one common share and one share purchase warrant, at a conversion price of CAD 0.10 per unit. Each share purchase warrant will have an exercise price of CAD 0.10 and will expire on August 31, 2026. The debentures bear 10% interest rate and matures on February 28, 2026.공시 • Jan 02BetterLife Pharma Inc. announced that it has received CAD 0.3 million in fundingBetterLife Pharma Inc. announce that it has closed a non-brokered private placement of 10% convertible debentures for principal[al amount of CAD 300,000 on January 2, 2024. The convertible debenture interest rate of 10%, will mature on June 30, 2025. The Convertible Debentures are convertible at the option of the holder into units of the Company, consisting of one common share and one share purchase warrant, at a conversion price of CAD 0.10 per unit. Each share purchase warrant will have an exercise price of CAD 0.10 and will expire on December 31, 2025. The transaction included participation from Dr. Ahmad Doroudian, Chief Executive Officer of the Company who subscribed a total of CAD 125,000 principal amount of convertible debentures under the Offering.공시 • Dec 18BetterLife Pharma Inc. announced that it has received CAD 0.2 million in fundingBetterLife Pharma Inc. announce that it has closed a non-brokered private placement of 2,000,000 units at an issue price of CAD 0.10 per Unit for aggregate gross proceeds of CAD 200,000 on December 18, 2023. Each Unit is comprised of one common share and one warrant. Each warrant entitles the holder thereof to acquire one common share at an exercise price of CAD 0.10 at any time up to 24 months from the closing of the Offering. The Units sold pursuant to the Offering will be subject to a four month hold period pursuant to applicable Canadian securities laws. The transaction included participation from Dr. Ahmad Doroudian, Chief Executive Officer of the Company who subscribed a total of 1,000,000 Units under the Offering.공시 • Dec 01Us Patent and Trademark Office Publishes Betterlife’S Comprehensive Patent for Betr-001 and Other Lsd DerivativesBetterLife Pharma Inc. announced that its patent application for BETR-001 and LSD derivatives titled “LSD derivatives, synthesis & method for treatment of diseases and disorders” has been published by the United States Patent and Trademark Office under publication number US-2023/0357243-A1 and available for access on USPTO’s databases. BetterLife is presently developing one of these derivatives: a 2-bromo derivative of LSD (BETR-001) that is non-hallucinogenic and, in preclinical animal models, has been shown to be a potent neuroplastogen and have efficacy against depression/anxiety states. This published U.S. patent is part of a developing international patent portfolio which cover new compositions of 2-bromo-LSD and other LSD derivatives. In addition to composition claims, these applications also cover a novel method for making non-hallucinogenic LSD derivatives that does not involve the use of controlled substances at any stage. The applications also cover use of these derivatives in the treatment of a range of neuropsychiatric and neurological conditions, including depression, anxiety, cluster headaches and neuropathic pain. Betterlife is also pleased that its efforts to develop novel therapies for mental disorders were highlighted in the November 8 edition of The Atlantic. The Atlantic journal highlighted the potential of the BETR-001 program, as a non-hallucinogenic analog of LSD, in an article entitled “What If Psychedelics’ Hallucinations Are Just a Side Effect?” The article discusses, in part, that a growing number of key opinion leaders in neuroscience now believe that the hallucination caused by psychedelics is just a side effect and not necessary to produce mental-health benefits by this class of drugs. BETR-001 is currently undergoing IND-enabling studies and projected to enter human trials in 2024.공시 • Jul 14BetterLife Pharma Inc. announced that it has received CAD 0.22 million in fundingBetterLife Pharma Inc. announced a non-brokered private placement of 2,200,000 units at a price of CAD 0.10 per non-brokered unit for aggregate gross proceeds of CAD 220,000 on July 13, 2023. Each non-brokered unit is comprised of one common share and one warrant. Each warrant entitles the holder thereof to acquire one common share at an exercise price of CAD 0.15 at any time up of 60 months from the closing of the offering. The units sold pursuant to the offering will be subject to a four month hold period pursuant to applicable Canadian securities laws.공시 • Jun 23BetterLife Pharma Inc. Announces Appointment of Steven Sangha as Corporate Development AdvisorBetterLife Pharma Inc. announced the appointment of Dr. Steven Sangha as corporate development advisor to the Company. Dr. Sangha has over 25 years of experience in investment banking, business development and asset management. His extensive experience with public company governance and compliance, and finance has led him to successfully run a Private Fund Family Office. Dr. Sangha’s interest in the biotechnology industry has allowed positive growth for early-stage companies with his consummate efforts in assessment, development and financial support. Dr. Sangha holds a Doctorate of Dental Surgery from the University of Western Ontario in London, Ontario, and a Bachelor of Pharmaceutical Science from the University of British Columbia in Vancouver, British Columbia.공시 • Jun 09BetterLife Pharma Inc. Continues Progress on BETR-001 IND-Enabling StudiesBetterLife Pharma Inc. announced that the IND-enabling studies BetterLife's 2-bromo-LSD ("BETR -001") continue to progress. BETR-001 is a non-hallucinogenic Lysergic Acid Diethylamide ("LSD") derivative molecule. BetterLife has previously completed the preclinical pharmacological profiling of BETR-001, which showed that BETR-001 has robust activity in various depression/an anxiety animal models without hallucinogenic activity. The BETR-001 IND-enabling animal toxicology studies are now in various stages of completion. The in-life portion of the 28-day repeat dose GLP toxicology study in dogs has now been completed, and the histopathological analyses are ongoing. The GMP manufacturing of BETR-001 drug substance is also in its final stages.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 BETR.F 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: BETR.F 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장BetterLife Pharma 배당 수익률 vs 시장BETR.F의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (BETR.F)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Pharmaceuticals)1.9%분석가 예측 (BETR.F) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 BETR.F 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 BETR.F 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 BETR.F 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: BETR.F 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/09 01:35종가2026/07/09 00:00수익2026/04/30연간 수익2026/01/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스BetterLife Pharma Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Jul 08Betterlife Pharma Engages Nucro-Technics to Complete the Last Glp Toxicology Study of Betr-001 Required by the Fda for Ind and Phase 1BetterLife Pharma Inc. has entered into an agreement with Nucro-Technics Inc. to conduct the last IND-enabling GLP toxicology study with BETR-001 for its planned IND and Phase 1 program. BETR-001 is 2-bromo-lysergic acid diethylamide (2-Br-LSD), a non-hallucinogenic derivative of LSD. BETR-001 is a potent neuroplastogen and an agonist of the 5-HT1B, 5-HT1D, and 5-HT1F receptors, which are clinically validated targets of migraine therapies, as well as the 5-HT2A receptors. BETR-001 is being developed initially for migraine and cluster headache, two disabling headache disorders with substantial unmet medical needs. The BETR-001 IND filing is projected for the First Quarter 2027.
공시 • Jun 23BetterLife Pharma Inc. announced that it has received CAD 2 million in fundingOn June 22, 2026, BetterLife Pharma Inc. has closed the transaction.
공시 • Jun 16BetterLife Pharma Inc. announced that it expects to receive CAD 2 million in fundingBetterLife Pharma Inc. has announced a non-brokered private placement of 10% convertible debenture of the company to raise gross proceeds of CAD 2,000,000 on June 15, 2026. The debenture are 100% convertible into common units of the company at a conversion price value of CAD 0.06 per unit and carry interest rate of 10% and with each unit comprising of one common share and one share purchase warrant exercisable at CAD 0.10 for three years from issuance. All securities issued in connection with the Financing will be subject to a statutory hold period of four months and one day from the date of issuance in accordance with applicable Canadian securities laws. A director and insider of the company intends to participate in the financing by subscribing for CAD 2,000,000 of the Debenture. The bonds will mature one year from closing. The transaction is expected to close on June 25, 2026.
공시 • Apr 18BetterLife Pharma Inc. announced that it has received CAD 0.4996 million in fundingOn April 17, 2026, BetterLife Pharma Inc. closed the transaction. Dr. Ahmad Doroudian, chief executive officer of the company, subscribed for a total of 1,250,000 units under the offering.
공시 • Apr 09BetterLife Pharma Inc. announced that it expects to receive CAD 0.5 million in fundingBetterLife Pharma Inc announced non-brokered private placement offering to issue 7,142,857 unit at an issue price of CAD 0.07 for the proceeds of CAD 499,999.99 on April 8, 2026. Each unit consisting of one common share in the capital of the company and one full common share purchase warrant. Each warrant will entitle the holder to purchase one common share at an exercise price of CAD 0.10 for up to two years following the date of the closing of the private placement. The offering is expected to close on or about April 17, 2026, and is subject to execution of agreements by the placees and to certain conditions, including, but not limited to, the receipt of all necessary regulatory approvals, including the approval of the Canadian Securities Exchange. All securities issued in connection with the offering will be subject to a four-month-and-one-day statutory resale restriction pursuant to applicable Canadian securities laws.
공시 • May 28Betterlife Pharma Inc. Provides Scientific Update on Neuroplastogenic Activity of Betr-001BetterLife Pharma Inc. recently presented a scientific update at Bloom Burton Conference on May 5, 2025 in Toronto, Canada. The emerging new paradigm in treating psychiatric and neurological disorders is the ability of a drug to enable the brain to rewire by growing new dendrites and spines, which enables new connections between neurons. Thisphenon is called neuroplasticity and the drug that is able to induce such an effect is called a neuroplastogen. BetterLife reported data at the Bloom Burton Conference showing that BETR-001 is a potent neuroplastogen. Only BETR-001 treatment was able to significantly induce formation of new spines (green stain) in cultured neurons. Based on its excellent neuroplasticity data, its neuroreceptor activation profile and preliminary data obtained in animal models, BETR-001 is projected to be effective in treating various psychiatric and neurological disorders including depression, anxiety, PTSD, traumatic brain injury, migraines and neuropathic pain. BETR-001 is non-hallucinogenic and not a controlled substance. BetterLife has been granted a composition of matter patent on BETR-001 by the USPTO. BetterLife has had its BETR-001 pre-IND meeting with the FDA and has completed most of the required IND-enabling studies. The BETR-001 IND filing and start of human trials are projected for first first half of 2026.
공시 • May 19BetterLife Pharma Inc., Annual General Meeting, Jul 23, 2025BetterLife Pharma Inc., Annual General Meeting, Jul 23, 2025.
공시 • May 15BetterLife Pharma Inc. Provides Scientific Update of Mechanism of Action of BETR-001 in Treatment of Psychiatric DisordersBetterLife Pharma Inc. recently presented a scientific update at Bloom Burton Conference on May 5, 2025 in Toronto, Canada. BetterLife reported that its proprietary compound, BETR-001, is showing very promising preclinical data of its breakthrough ability to provide therapeutic effect in depression/an anxiety animal models. Current methods of treating depression/an anxiety primarily focus on increasing the level of one of the three neurotransmitters: serotonin, norepinephrine and/or dopamine in the brain. Each neurotransmitter has different receptor targets, and each receptor performs different functions. Current treatments are usually reuptake inhibitors such as SSRIs (selective serotonin reuptake inhibitors) and by increasing the amount of a neurotransmitter, all its receptors are activated. What is needed are new treatments that activate the neuroreceptors themselves, and more importantly, only selective subsets of these receptors. The therapeutic effects of BETR-001 seen in preclinical models are primarily driven by its activation (agonism) of serotonin's 5HT2A receptor. Not only does BETR-001 activate the 5HT2A receptor, which plays a key role in depression/an anxiety, this activation is via a mechanism that allows for a highly efficacious therapeutic effect without hallucinogenic side effects. This stands in contrast to other potent 5HT2A activators, such as LSD, psilocybin and other psychedelics. BetterLife has reported on the details of BETR-001 activation of the 5HT2A receptor previously (Lewis et al., Cell Reports, 2023). Recently studies have shown that the activation of the 5 HT2A receptor above 70% leads to hallucination (Wallach et al., Nature Communications, 2023). BetterLife believes that BETR-001's novel mechanism of action provides a new paradigm for treatment of psychiatric disorders such as depression, anxiety and PTSD. It activates the 5HT2A receptor partially but stays below the hallucination threshold. In addition, unlike LSD, psilocybin, MDMA and other such agents BETR-001 is not an activator of the 5HT2B receptor. Activation of 5HT2B has been linked to cardiac safety. The neuroreceptor selectivity of BETR-001 in this regard is another of its key advantages over other competitor agents. An additional benefit of BETR-001 is that repeated dosing does not induce tolerance, unlike classic agents like LSD. This allows daily administration if needed. Furthermore, the lack of hallucinations with BETR-001 means it is a non-controlled substance and patient self-administration at home is possible. Finally, an overarching property of BETR-001 is a very potent neuroplastogen. BetterLife has been granted a composition of matter patent on BETR-001 by the USPTO. BetterLife has had its BETR-001 pre-IND meeting with the FDA and has completed most of the required IND-enabling studies. The BETR-001 IND filing and start of human trials are projected for H1 2026. BetterLife is considering the development of BETR-001 for treatment of various psychiatric and neurological disorders. BETR-001 for treatment the treatment of various psychiatric and neurological diseases.
공시 • Mar 31BetterLife Pharma Inc. Appoints Steven Sangha to its Board of DirectorsBetterLife Pharma Inc. announced it has appointed Dr. Steven Sangha to its Board of Directors. Dr. Sangha has over 25 years of business experience, including investment banking, business development and asset management. His extensive background with public company governance, compliance and finance has led him to run a successful Private Fund Family Office. Dr. Sangha holds a Doctorate of Dental Surgery from the University of Western Ontario in London, Ontario, and a Bachelor of Pharmaceutical Science from the University of British Columbia in Vancouver, British Columbia.
공시 • Nov 27BetterLife Pharma Inc. Obtains Cardiac Safety Data for BETR-001BetterLife Pharma Inc. announced it has completed one of its IND-enabling cardiac safety studies of BETR-001. These GLP in vitro studies demonstrated that BETR-001 has minimal impact on the human ether- a-go-go-related gene (hERG) channel, an important ion channel for cardiac functioning.
공시 • Oct 23BetterLife Pharma Inc. Obtains Favourable Genotoxicity Data for Oral BETR-001BetterLife Pharma Inc. announced it has completed one of its IND-enabling genotoxicity studies of BETR-001. The studies demonstrated that oral BETR-001, even at very high doses, does not show any evidence of bone marrow toxicity or mutagenic (DNA mutation) and clastogenic (chromosome damage) activities. The GLP genotoxicity studies conducted on BETR-001 included in vitro bacterial reverse mutation assay, in vitro micronucleus test, and in vivo micronucleus test in male and female rats. These studies are a critical component of the safety assessment required by the U.S. Food and Drug Administration (FDA) and needed for entry into clinical trials.
공시 • Aug 29BetterLife Pharma Inc. announced that it expects to receive CAD 1.1 million in fundingBetterLife Pharma Inc announced a non brokered private placement offering of 7,333,333 units issued at a price of CAD 0.15 per unit for gross proceeds CAD 1,099,999.95 on August 29, 2024. Each unit consisting of one common share in the capital of the Company and one full common share purchase warrant. Each Warrant will entitle the holder to purchase one Common Share at an exercise price of CAD 0.20 for up to two years following the date of the closing of the Private Placement. The close is subject to the receipt of all necessary regulatory and other approvals which will be announced as soon as it has been completed.
공시 • Jul 03BetterLife Pharma Inc. announced that it has received CAD 0.175 million in fundingOn July 2, 2024, BetterLife Pharma Inc. closed the transaction.
공시 • May 15BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001BetterLife Pharma Inc. announced it has completed its animal GLP cardiopulmonary safety study of BETR-001. The study demonstrated that oral BETR-001 at doses over 100-fold the projected starting dose in upcoming human trials did not show any significant cardiopulmonary pharmacological safety issues in animals. Cardiopulmonary safety (also known as telemetry) studies investigate the effect of a drug in animals using surgically implanted transmitters to assess blood pressure, electrocardiography (ECG), lung respiration, body temperature, and general activity level. The BETR-001 cardiopulmonary study found no BETR-001 related effects on ECG intervals, respiratory parameters, core body temperature, or activity levels.
공시 • May 03BetterLife Pharma Inc. Advances BETR-001 IND-Enabling StudiesBetterLife Pharma Inc. announced that it has advanced in its IND-enabling studies for BETR-001, a non-hallucinogenic derivative of LSD (lysergic acid diethylamide). The IND-enabling metabolism and genotoxicity GLP studies have been initiated. BetterLife has had its BETR-001 pre-IND meeting with the FDA, and projects to file the BETR-001 IND by end of 2024.
공시 • Apr 13BetterLife Pharma Inc., Annual General Meeting, Jun 25, 2024BetterLife Pharma Inc., Annual General Meeting, Jun 25, 2024.
공시 • Mar 05BetterLife Pharma Inc. announced that it expects to receive CAD 0.1 million in fundingBetterLife Pharma Inc. announced a private placement to issue convertible debentures for the gross proceeds of CAD 100,000 on March 4, 2024. The transaction will include participation from individual investor such as Ahmad Doroudian for CAD 100,000.
공시 • Mar 04BetterLife Pharma Inc. announced that it has received CAD 0.065 million in fundingBetterLife Pharma Inc. announced a private placement to issue 10% convertible debentures for the gross proceeds of CAD 65,000 on March 4, 2024. The Convertible Debentures are convertible at the option of the holder into units of the Company, consisting of one common share and one share purchase warrant, at a conversion price of CAD 0.10 per unit. Each share purchase warrant will have an exercise price of CAD 0.10 and will expire on August 31, 2026. The debentures bear 10% interest rate and matures on February 28, 2026.
공시 • Jan 02BetterLife Pharma Inc. announced that it has received CAD 0.3 million in fundingBetterLife Pharma Inc. announce that it has closed a non-brokered private placement of 10% convertible debentures for principal[al amount of CAD 300,000 on January 2, 2024. The convertible debenture interest rate of 10%, will mature on June 30, 2025. The Convertible Debentures are convertible at the option of the holder into units of the Company, consisting of one common share and one share purchase warrant, at a conversion price of CAD 0.10 per unit. Each share purchase warrant will have an exercise price of CAD 0.10 and will expire on December 31, 2025. The transaction included participation from Dr. Ahmad Doroudian, Chief Executive Officer of the Company who subscribed a total of CAD 125,000 principal amount of convertible debentures under the Offering.
공시 • Dec 18BetterLife Pharma Inc. announced that it has received CAD 0.2 million in fundingBetterLife Pharma Inc. announce that it has closed a non-brokered private placement of 2,000,000 units at an issue price of CAD 0.10 per Unit for aggregate gross proceeds of CAD 200,000 on December 18, 2023. Each Unit is comprised of one common share and one warrant. Each warrant entitles the holder thereof to acquire one common share at an exercise price of CAD 0.10 at any time up to 24 months from the closing of the Offering. The Units sold pursuant to the Offering will be subject to a four month hold period pursuant to applicable Canadian securities laws. The transaction included participation from Dr. Ahmad Doroudian, Chief Executive Officer of the Company who subscribed a total of 1,000,000 Units under the Offering.
공시 • Dec 01Us Patent and Trademark Office Publishes Betterlife’S Comprehensive Patent for Betr-001 and Other Lsd DerivativesBetterLife Pharma Inc. announced that its patent application for BETR-001 and LSD derivatives titled “LSD derivatives, synthesis & method for treatment of diseases and disorders” has been published by the United States Patent and Trademark Office under publication number US-2023/0357243-A1 and available for access on USPTO’s databases. BetterLife is presently developing one of these derivatives: a 2-bromo derivative of LSD (BETR-001) that is non-hallucinogenic and, in preclinical animal models, has been shown to be a potent neuroplastogen and have efficacy against depression/anxiety states. This published U.S. patent is part of a developing international patent portfolio which cover new compositions of 2-bromo-LSD and other LSD derivatives. In addition to composition claims, these applications also cover a novel method for making non-hallucinogenic LSD derivatives that does not involve the use of controlled substances at any stage. The applications also cover use of these derivatives in the treatment of a range of neuropsychiatric and neurological conditions, including depression, anxiety, cluster headaches and neuropathic pain. Betterlife is also pleased that its efforts to develop novel therapies for mental disorders were highlighted in the November 8 edition of The Atlantic. The Atlantic journal highlighted the potential of the BETR-001 program, as a non-hallucinogenic analog of LSD, in an article entitled “What If Psychedelics’ Hallucinations Are Just a Side Effect?” The article discusses, in part, that a growing number of key opinion leaders in neuroscience now believe that the hallucination caused by psychedelics is just a side effect and not necessary to produce mental-health benefits by this class of drugs. BETR-001 is currently undergoing IND-enabling studies and projected to enter human trials in 2024.
공시 • Jul 14BetterLife Pharma Inc. announced that it has received CAD 0.22 million in fundingBetterLife Pharma Inc. announced a non-brokered private placement of 2,200,000 units at a price of CAD 0.10 per non-brokered unit for aggregate gross proceeds of CAD 220,000 on July 13, 2023. Each non-brokered unit is comprised of one common share and one warrant. Each warrant entitles the holder thereof to acquire one common share at an exercise price of CAD 0.15 at any time up of 60 months from the closing of the offering. The units sold pursuant to the offering will be subject to a four month hold period pursuant to applicable Canadian securities laws.
공시 • Jun 23BetterLife Pharma Inc. Announces Appointment of Steven Sangha as Corporate Development AdvisorBetterLife Pharma Inc. announced the appointment of Dr. Steven Sangha as corporate development advisor to the Company. Dr. Sangha has over 25 years of experience in investment banking, business development and asset management. His extensive experience with public company governance and compliance, and finance has led him to successfully run a Private Fund Family Office. Dr. Sangha’s interest in the biotechnology industry has allowed positive growth for early-stage companies with his consummate efforts in assessment, development and financial support. Dr. Sangha holds a Doctorate of Dental Surgery from the University of Western Ontario in London, Ontario, and a Bachelor of Pharmaceutical Science from the University of British Columbia in Vancouver, British Columbia.
공시 • Jun 09BetterLife Pharma Inc. Continues Progress on BETR-001 IND-Enabling StudiesBetterLife Pharma Inc. announced that the IND-enabling studies BetterLife's 2-bromo-LSD ("BETR -001") continue to progress. BETR-001 is a non-hallucinogenic Lysergic Acid Diethylamide ("LSD") derivative molecule. BetterLife has previously completed the preclinical pharmacological profiling of BETR-001, which showed that BETR-001 has robust activity in various depression/an anxiety animal models without hallucinogenic activity. The BETR-001 IND-enabling animal toxicology studies are now in various stages of completion. The in-life portion of the 28-day repeat dose GLP toxicology study in dogs has now been completed, and the histopathological analyses are ongoing. The GMP manufacturing of BETR-001 drug substance is also in its final stages.